EAACI Congress 2024
BackL-OAS-CT 01 - Clinical trials
Friday 31 May, 16:45 PM -
18:15 PM Valencia, Spain
Innovation Hub
Oral Abstract Session on Clinical Trials
16:45
Long-Term Efficacy and Safety of Remibrutinib in Patients with Chronic Spontaneous Urticaria in the Phase 3 REMIX-1 and REMIX-2 Studies
16:57
Donidalorsen for the treatment of hereditary angioedema: Results from a phase 3, randomised, placebo-controlled trial
17:09
Prospective, pilot, phase 1 study of iPUMP© in patients starting sublingual allergen immunotherapy (Staloral©)
17:21
Self-reported treatment preferences of patients switching from prior prophylactic therapies to donidalorsen for the treatment of hereditary angioedema: Results from the phase 3 OASISplus study
17:33
Long-term safety of donidalorsen for the treatment of hereditary angioedema: Results from the phase 3 open-label extension OASISplus study
17:45
A randomized, double-blind, phase 2a study of covalent Bruton’s tyrosine kinase inhibitor TAS5315 in patients with chronic spontaneous urticaria with an inadequate response to H1-antihistamines
17:57
Oral Sebetralstat for On-demand Treatment of Hereditary Angioedema: Phase 3 KONFIDENT Trial Results
